Biosense Webster Launches Octaray Mapping Catheter with Trueref Technology

Johnson & Johnson (J&J) subsidiary Biosense Webster has launched its Octaray Mapping Catheter with Trueref Technology.

The catheter was developed for the mapping of cardiac arrhythmias, including atrial fibrillation. It has eight splines, along with improved electrode-spacing options that would provide shorter and more efficient mapping times than the company’s Pentaray NAV ECO mapping catheter, said Biosense Webster.

These reductions in time could also shorten overall ablation procedure times, the company added.

The Octaray device is both FDA-cleared and CE-marked.